share their discovery that a cytokine called interleukin-12 (IL-12) acts like a switch to direct which antibody response B ...

due to the limitations experienced with prior research utilising interleukin-12 (IL-12), which is often considered to be one of the “holy grails” in cancer immunotherapy. IL-12 is a powerful ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

Lipopolysaccharide (LPS) induction of the gene encoding interleukin 12 p40 requires remodeling of a promoter-encompassing nucleosome and the Toll-like receptor (TLR)–mediated activation of a c ...

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).